相关实验视频

Updated: Jan 12, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

揭露tectorigenin:一种新的铁灭诱导剂,在膀癌中向EGFR

Jiancheng Zhai¹, Rong Tan², Shenglan Yuan³

¹Department of Urology & Andrology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, No. 71 Bao Shan North Road, Yunyan District, Guiyang 550001, Guizhou, China; School of Pharmacy, Zhejiang Chinese Medical University 310053, Hangzhou, China.

Phytomedicine : international journal of phytotherapy and phytopharmacology

|November 2, 2025

概括

天然化合物Tectorigenin通过向表皮生长因子受体 (EGFR) 来诱导细胞死亡的一种形式ferroptosis,从而有效地抑制膀癌的生长. 这一发现为膀癌治疗提供了新的治疗策略.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
生物化学生化学

背景情况:

膀癌由于发病率和死亡率高,给全球健康带来了重大挑战.
来自Belamcanda chinensis的Tectorigenin,表现出有希望的抗癌特性.

研究的目的:

阐明tectorigenin在对抗膀癌的有效性和潜在机制.
探索tectorigenin作为膀癌的新型治疗剂的潜力.

主要方法:

使用了体外测试 (CCK8,光,流细胞计,TEM) 和体内异种移植模型.
西方涂抹,铁灭分析,分子动力学和对接研究研究了机制.
分析了关键的分子标和信号通路.

主要成果:

在体内,Tectorigenin显著抑制了膀瘤的生长,与西斯普拉丁相当,没有观察到器官毒性.
在实验室中,tectorigenin抑制了增殖,诱导了亡,增加了活性氧物种 (ROS),并降低了线粒体膜潜力 (MMP).
构造原蛋白通过损害线粒体,增加Fe2+和降低xCT,GPX4和GSH水平来触发铁亡,而deferoxamine (DFO) 和表皮生长因子 (EGF) 则可以逆转效应.

结论:

在膀癌中,Tectorigenin作为一种新的铁亡诱导剂,特别是通过向表皮生长因子受体 (EGFR) 来起作用.
这项研究揭示了tectorigenin的新疗法机制,为向膀癌治疗铺平了道路.

关键词:

膀癌是一种癌症.皮肤表皮生长因子受体.铁化是铁化的一种.构造原生素是一种构造原生素.

更多相关视频

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

In Vivo Targeting of Neural Progenitor Cells in Ferret Neocortex by In Utero Electroporation

In Vivo Targeting of Neural Progenitor Cells in Ferret Neocortex by In Utero Electroporation

Published on: May 6, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...